Articles On Neuren Pharmaceuticals (ASX:NEU)

ASX health stocks fall 0.32% in the past five days, despite rise in broader markets Neuren Pharmaceutical announces its DAYBUE drug officially available in US to treat Rett Syndrome Impedimed quarterly results in line with expectations wit...

Australian company Neuren Pharmaceuticals (ASX:NEU) is set to receive a US$40 million milestone payment following the US launch of its treatment for Rett syndrome.

ShareCafeASX recoups some earlier losses to close 0.29% lower by Peter Milios   At the closing bell, the S&P/ASX 200 was 0.29 per cent lower at 7,360.20, primarily due to a 1.9 per cent decline in the energy sector, with Woodside (ASX:W...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

The ASX slumped by 0.4% today as the RBA released its April minutes Core Lithium jumped 8pc after increasing its MRE BlackRock ditched its 60/40 strategy   Local shares fell 0.4% on Tuesday after the RBA minutes revealed the central bank...

The S&P/ASX 200 Index (ASX: XJO) is out of form on Tuesday and on course to record a disappointing decline. In afternoon trade, the benchmark index is down 0.5% to 7,345.8 points. Four ASX shares that are not letting that hold them bac...

Neuren’s breakthrough drug DAYBUE starts selling in the US Orthocell commences nerve repair study   Market darling Neuren Pharma (ASX:NEU) jumped 4% today after announcing that DAYBUE (trofinetide) is now officially available for the trea...

The leading investors from Wilson Asset Management (WAM) have shared thoughts on two ASX shares. WAM operates several listed investment companies (LICs). Some, like WAM Leaders Ltd (ASX: WLE), focus on larger companies. Meanwhile, WAM Cap...

Investors on Stake have been turning to gold to position for market volatility as price of precious metal rises Following RBA’s rate pause Stake has seen a 150% rise in investors adding Domino’s Pizza to their watchlist Neuren Pharmaceutic...

ASX health stocks rise 0.97% in the past five days in line with broader markets Impedimed up 99% after BIS tech named in latest US NCCN guidelines for lymphoedema  EBR Systems to release top line results at cardiac conference Heart Rhythm...

Several ASX health stocks are seeking US FDA approval for drugs/devices in the near future Telix Pharmaceuticals is chasing renal cancer imaging approval for TLX-250 CDx Aroa is awaiting an FDA decision on the required regulatory pathway...

Prescient Therapeutics is hoping to follow in the footsteps of Neuren Pharmaceuticals after positive results from its latest Phase 1b clinical trial. Prescient Therapeutics (ASX:PTX) will seek approval from the US Food and Drug Administrat...

Healius gets takeover offer from ALC, a company more than half its size Neurotech will launch Phase 2 clinical trial in Rett Syndrome Germany allows Invex to commence the IIH EVOLVE Phase 3 clinical trial   Healius gets takeover offer fro...

Saturday March 11 was a typical balmy autumnal afternoon in Melbourne, but Neuren (ASX:NEU) chief Jon Pilcher was despondent as he awaited news from the company’s US partner Acadia on whether the US Food and Drug Administration (FDA) had ap...

ASX health stocks fall 1.5% in the past five days, broader markets fall on global banking concerns Neuren Pharmaceuticals has soared 60% after FDA approves its drug for Rett’s syndrome  Antisense starts chronic monkey toxicology study of A...

The S&P/ASX 200 Index (ASX: XJO) is on course to end the week with a small gain. In afternoon trade, the benchmark index is up 0.2% to 6,978.3 points. Four ASX shares that are climbing more than most today are listed below. Here’s w...

The S&P/ASX 300 index may be trading notably lower than its recent highs, but that hasn’t stopped a couple of shares on the index from climbing to record highs today. The two ASX 300 shares that have reached these milestones are list...

Amidst a sea of red, the Neuren share price has skyrocketed in recent days following a world first approval for the biotech's treatment of Rett syndrome. -Nueren share price surged by more than 50% in four days-Neuren's tronefide becomes fi...

Local shares bounced back on Wednesday following a strong rally in New York overnight Neuren was once again the best performing large cap today Former PM Paul Keating ashed out at the AUKUS deal   The ASX 200 bounced back on Wednesday as...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) on course for a much-needed gain. At the time of writing, the benchmark index is up 0.3% to 7,029.4 points. Four ASX shares that are climbing more than most today are listed below....

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is racing higher again on Wednesday. In morning trade, the biotech company’s shares are up a further 14% to a multi-year high of $11.36. This means the ASX 300 share has now risen a w...

ASX hammered as bank-driven fear grips the market like a python round a possum XEC Emerging Companies falls more than 2.0% because they’re young and don’t know any better Safe haven goldies still managed to make bank. Sorry… poor choice of...

The ASX fell 1.6% on Tuesday on concerns of a global meltdown following SVB’s collapse Gold stocks and Bitcoin gained as Treasury yields collapsed Goldman Sachs now expects the Fed to keep rates on hold this month   The ASX 200 fell 1.6%...

The S&P/ASX 200 Index (ASX: XJO) is out of form again on Tuesday. In afternoon trade, the benchmark index is down 1.65% to 6,992.1 points. Four ASX shares that are not letting that hold them back today are listed below. Here’s why th...

A major win for Australian company Neuren Pharmaceuticals (ASX:NEU) with the US FDA approving its treatment for Rett syndrome.

ASX weathers a US bank collapse storm to finish the day down just 0.5% XEC Emerging Companies index down 0.84% because it was out partying all weekend. The Goldies take the gongs, after the precious metal jumped more than 1.0%   Looking a...

ShareCafeTech and Financials drag ASX 0.5% lower at the close by Peter Milios   On Monday, the S&P/ASX 200 decreased by 0.5 per cent, or 35.9 points, to 7108.8 due to losses in the financials and technology sectors. Gold miners performe...

13 Mar 2023 - A snapshot of the stocks on the move featuring Neuren Pharmaceuticals (ASX:NEU), Metro Mining (ASX:MMI) and Meteoric Resources (ASX:MEI).

The S&P/ASX 200 Index (ASX: XJO) has started the week in a subdued fashion. At the time of writing, the benchmark index is off its lows but down 0.2% to 7,130.1 points. Four ASX shares that are not letting that hold them back today ar...

ShareCafeASX down 0.61% at noon as SVB saga continues by Peter Milios   The collapse of Silicon Valley Bank has caused concern in the US banking and technology industries, reminding investors of the risks they had ignored. Bank stocks have...

ShareCafeStocks of the Hour: NEU, MMI, MEI                    Neuren Pharmaceuticals (ASX:NEU) has announced that they have received an FDA approval for their DAYBUE product, which is the first approved treatment for Rett syndrome. In...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Melbourne-based Neuren Pharmaceuticals (ASX: NEU) has announced that its North American partner Acadia Pharmaceuticals (NASDAQ: ACAD) has received US Food and Drug Adm...

Neuren Pharma gets a ‘historic’ FDA approval for DAYBUE to treat Rett syndrome Genetic Technologies published another research paper HITIQ sells 200 Nexus Head Impact Sensors to Monash University   Neuren Pharmaceuticals (ASX:NEU) surged...

The US Food and Drug Administration (FDA) approves Neuren Pharmaceuticals’ (NEU) North American partner’s trofinetide drug as a treatment for Rett syndrome Trofinetide, marketed under the brand name DAYBUE, is now the first drug approved...

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is starting the week very positively. In morning trade, the ASX All Ords biotech company’s shares are up 27% to a multi-year high of $9.74. Why is the ASX All Ords biotech stock jumpi...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Neuren’s compound trofinetide has been granted US FDA approval for the treatment of Rett’s syndrome Trofinetide has been given brand name DAYBUE and is expected to be available in the US by end of April 2023 Healthcare analysts welcome ne...

ASX health stocks fall 1.87% in the past five days as reporting season ends Healius moves to a statutory loss of ~$29 million following reduced demand for Covid-19 testing Catalysts in next few months for several ASX health stocks which co...

Neuren Pharmaceuticals (ASX:NEU) has announced the appointment of Joe Basile as an independent non-executive director.

The US FDA is expected to decide on March 12 whether it approves Neuren’s trofinetide for Rett’s syndrome If the drug is approved it will be a game-changer financially for the biotech Australia has had only a few FDA approvals for drugs/d...

Neuren Pharmaceuticals (ASX:NEU) has announced that the US FDA has reviewed Neuren’s Investigational New Drug application for NNZ-2591 in Prader-Willi syndrome.

Cynata Therapeutics’ chief medical officer, Jolanta Airey, gives a step-by-step guide on what biotechs need to do to commence a clinical trial Which ASX biotechs have an IND submission to the FDA and will start a clinical trial soon?   Wh...

Universal Bio completes patient recruiting for Xprecia Prime study Neuren Pharma given approval by FDA to start Phase 2 trial Chimeric completes Phase 1A trial with flying colours   Universal Bio to lodge FDA submission this quarter Unive...

Neuren Pharmaceuticals (NEU) receives the green light to go ahead with a phase two clinical trial testing its NNZ-2591 drug on children with Prader-Willi syndrome It comes after the company applied for investigational new drug approval f...

ASX health stocks rise 4.6% this week with positive signs of being back in favour Volpara soars after announcing its first net cash flow positive quarter Morgans basket of healthcare stock picks for 2023 faring well,  all up YTD Healthca...

The All Ordinaries Index (ASX: XAO) is back in the green on Wednesday, driven higher by four shares leaping to new 52-week highs. Right now, the All Ordinaries Index is up 0.12%, trading at 7,606.9 points. Let’s take a closer look at fou...

The S&P/ASX 300 Index (ASX: XKO) is full of interesting businesses. A leading fund manager has picked out two lower-profile ASX 300 shares that could do well. Wilson Asset Management (WAM) operates a number of listed investment compani...

2023 off to a bit of a dismal start, down 1.3% on the opening day of trade GreenX soaring after rumblings from Poland over $1.3 billion payday Chinese markets gain before the rest of the trading world gets back from holidays   For about 1...

The ASX tumbled over 1% in the first trading day of 2023 Stocks were sold across all sectors, with some blaming lack of liqudity Properties across all Australia fell again in December   It wasn’t the start of year investors had wanted to...

The new year is off to a disastrous start for the All Ordinaries Index (ASX: XAO) and most of the shares that call it home. Despite posting a strong start to Tuesday’s session ­– it jumped as high as 0.47% in early trade – the bench...